<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383471</url>
  </required_header>
  <id_info>
    <org_study_id>KS-INV-02-3</org_study_id>
    <nct_id>NCT03383471</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis</brief_title>
  <official_title>A Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Invossa K Injection in Patients Diagnosed as Knee Osteoarthritis With Kellgren &amp; Lawrence Grade 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kolon Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kolon Life Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of intraarticular Invossa K
      Injection patients diagnosed with Kellgren &amp; Lawrence grade 2 knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IKDC (International knee documentation committee) Subjective Knee Evaluation</measure>
    <time_frame>Week 0 and 52</time_frame>
    <description>Changes in IKDC Subjective Knee Evaluation (score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>100 mm VAS (Visual analogue scale)</measure>
    <time_frame>Week 0 and 52</time_frame>
    <description>Changes in 100 mm VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index) score</measure>
    <time_frame>Week 0, 26, 39 and 52</time_frame>
    <description>Changes in WOMAC (score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC Subjective Knee Evaluation</measure>
    <time_frame>Week 0, 26 and 39</time_frame>
    <description>Changes in IKDC Subjective Knee Evaluation (score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100 mm VAS</measure>
    <time_frame>Week 0, 26 and 39</time_frame>
    <description>Changes in 100 mm VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI (Outcome measures in rheumatology-Osteoarthritis research society international) response rate</measure>
    <time_frame>Week 26, 39 and 52</time_frame>
    <description>OMERACT-OARSI response rate after administration (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI scan</measure>
    <time_frame>Week 0, and 52</time_frame>
    <description>Changes in MRI scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Space Width</measure>
    <time_frame>Week 0, and 52</time_frame>
    <description>Changes in Joint Space Width (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker (CTX-I) in blood</measure>
    <time_frame>Week 0, 26, and 52</time_frame>
    <description>Levels of CTX-I in blood (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker (CTX-II) in urine</measure>
    <time_frame>Week 0, 26, and 52</time_frame>
    <description>Levels of CTX-II in urine (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication (Dosage)</measure>
    <time_frame>Week 0, 4, 12, 26, 39, and 52</time_frame>
    <description>Dosage of Rescue Medication (mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication (Frequency)</measure>
    <time_frame>Week 0, 4, 12, 26, 39, and 52</time_frame>
    <description>Frequency of Rescue Medication (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop-out rate</measure>
    <time_frame>Week 0, 4, 12, 26, 39, and 52</time_frame>
    <description>Drop-out rate (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason of drop-out</measure>
    <time_frame>Week 0, 4, 12, 26, 39, and 52</time_frame>
    <description>Reason of drop-out is recorded in CRF (Case Report Form), when the patient is dropped-out according to drop-out criteria (e.g. Withdraw a consent, Patients who can not continuously participate in study due to adverse events, Impossible to follow-up of the patient. etc.).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Invossa K Inj.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Invossa K Inj.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Invossa K Inj.</intervention_name>
    <description>Invossa K Inj.</description>
    <arm_group_label>Invossa K Inj.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 19 and older

          2. Patients with IKDC Subjective Knee Evaluation of ≤ 60 of the target knee.

          3. Patients with a score of ≥ 40 on the 100 mm pain VAS of the target knee.

          4. Patients with grade 2 osteoarthritis as determined by the radiographic criteria of
             Kellgren and Lawrence

          5. BMI should fall between 18.5 and 30

          6. Patients who satisfies the clinical/radiational criteria by the American College of
             Rheumatology guidelines, and applies to one of the following.

               -  Age &gt; 50 years old

               -  Morning stiffness &lt; 30 minutes

               -  Crepitus and Osteophytes

          7. With major lesions concentrated in one section of the knee, and with the major lesions
             considered the main cause of the clinical symptoms

          8. Patients with persistent symptoms in spite of conservative therapy for more than 3
             months : Improvement of 100 mm VAS are less than 10 mm after 3 months

          9. Healthy, with no major findings from the physical examination, hematology, serum
             chemistry, and urine tests, and no significant medical history

         10. Agreed to use an effective contraceptive method during the study period

         11. Voluntarily agreed to participate in this study, and signed the informed consent form

        Exclusion Criteria:

          1. Patients who had been administered with drugs such as oriental medicine, glucosamine
             and chondroitin within 14 days of baseline visit (But, possible to include after 14
             days of wash-out period)

          2. Patients taking steroidal anti-inflammatory medications within 14 days of baseline
             visit (But, possible to include after 14 days of wash-out period)

          3. Patients with severe pain in other areas that could effect the diagnosis of the
             symptoms

          4. Patients over Grade 3 osteoarthritis as determined by the radiographic criteria of
             Kellgren and Lawrence

          5. History of surgery like arthroendoscopy within the past 6 months on the target knee

          6. Patients who had been administered with immunosuppressants, including antirheumatic
             drugs (including methotrexate or antimetabolite), within the past 3 months

          7. History of injection within the past 3 months on the target knee

          8. Pregnant or breastfeeding female

          9. With another joint disease apart from degenerative arthritis

         10. Patients with hepatitis including carrier

         11. Patients with HIV and an infectious disease which is clinically uncontrolled

         12. Patients who have any of the following clinically significant diseases or have a
             medical history within 6 months :

               -  Clinically significant heart diseases which are considered by the investigator

               -  Uncontrolled hypertension : if the systolic blood pressure exceeds 160 mmHg or
                  diastolic blood pressure exceeds 100 mmHg in a sitting position

               -  Kidney disease

               -  Liver disease

               -  Endocrine disease

               -  Uncontrolled diabetes mellitus : HbA1c ≥ 9%

               -  Paget's disease, ochronosis, acromegaly, hemochromatosis, Wilson's disease

               -  Genetic diseases (hyperkinesia, collagen gene abnormality)

         13. Medical history of past or current malignant tumor

         14. Patients with a history of anaphylactic reactions

         15. Patients with a history of hypersensitivity reactions to the components of this drug,
             including dimethylsulfoxide, mannitol, dextran 40 or bovine proteins

         16. Participated in another clinical trial (using the investigational drug or a medical
             device) within 30 days before enrollment in this study

         17. Patients who administered the INVOSSA K inj.

         18. Considered inappropriate by the investigator for participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Chul Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Orthopedic Surgery, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University School of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University School of Medicine</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Medicine, Hanyang University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Medicine, Kyung Hee University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Borame Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrocyte cells</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

